Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wu Yang

Showing results (831-840 of 842) with videos related to

Pageof 85
Sort By:
Neuron|April 23, 2024
Growth hormone promotes myelin repair after chronic hypoxia via triggering pericyte-dependent angiogenesisShu-Yu Ren, Yu Xia, Bin Yu, et al.
Iscience|August 5, 2025
Integrated omics identifies molecular networks of brain-body interactions of brain injuryYuan-Hong Deng, Hong Wang, Jia-Hang Zhang, et al.
Journal of Plant Physiology|February 5, 2025
A Gln alteration influences leaf morphogenesis by mediating gibberellin levels in tobaccoQi-Li Mi, Hong-Tao Lv, Fei-Fei Huang, et al.
Neurology|October 15, 2021
Association Between Time to Endovascular Therapy and Outcomes in Patients With Acute Basilar Artery OcclusionHong Fei Sang, Jun Jie Yuan, Zhong Ming Qiu, et al.
World Journal of Gastroenterology|July 31, 2025
Efficacy and safety of triple therapy with vonoprazan for <i>Helicobacter pylori</i> eradication: A multicenter, prospective, randomized controlled trialRong-Shuang Han, Jing-Wen Hao, Tong Wang, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2019
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailabilityCharles G Clark, Karen A Rossi, James R Corte, et al.
Journal of Medicinal Chemistry|May 28, 2020
Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical SpeciesWu Yang, Yufeng Wang, Amy Lai, et al.
Journal of Medicinal Chemistry|September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic TherapyAndrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry|December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 GroupsJames R Corte, Donald J P Pinto, Tianan Fang, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agentYoon T Jeon, Wu Yang, Jennifer X Qiao, et al.
Pageof 85

Showing results (831-840 of 842) with videos related to

Sort By:
Pageof 85
Neuron|April 23, 2024
Growth hormone promotes myelin repair after chronic hypoxia via triggering pericyte-dependent angiogenesisShu-Yu Ren, Yu Xia, Bin Yu, et al.
Iscience|August 5, 2025
Integrated omics identifies molecular networks of brain-body interactions of brain injuryYuan-Hong Deng, Hong Wang, Jia-Hang Zhang, et al.
Journal of Plant Physiology|February 5, 2025
A Gln alteration influences leaf morphogenesis by mediating gibberellin levels in tobaccoQi-Li Mi, Hong-Tao Lv, Fei-Fei Huang, et al.
Neurology|October 15, 2021
Association Between Time to Endovascular Therapy and Outcomes in Patients With Acute Basilar Artery OcclusionHong Fei Sang, Jun Jie Yuan, Zhong Ming Qiu, et al.
World Journal of Gastroenterology|July 31, 2025
Efficacy and safety of triple therapy with vonoprazan for <i>Helicobacter pylori</i> eradication: A multicenter, prospective, randomized controlled trialRong-Shuang Han, Jing-Wen Hao, Tong Wang, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2019
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailabilityCharles G Clark, Karen A Rossi, James R Corte, et al.
Journal of Medicinal Chemistry|May 28, 2020
Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical SpeciesWu Yang, Yufeng Wang, Amy Lai, et al.
Journal of Medicinal Chemistry|September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic TherapyAndrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry|December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 GroupsJames R Corte, Donald J P Pinto, Tianan Fang, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agentYoon T Jeon, Wu Yang, Jennifer X Qiao, et al.
Pageof 85